Validation of a 46-Gene CCP RNA Signature for Predicting Prostate Cancer Death

May 21, 2014
Peter T. Scardino, MD, FACS

Peter T. Scardino, MD, FACS, discusses an analysis presented at the 2014 AUA Annual Meeting: Validation of a 46-gene cell cycle progression (CCP) RNA signature for predicting prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort.

Clinical Pearls

Peter T. Scardino, MD, FACS, Chair, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses an analysis presented at the 2014 AUA Annual Meeting: Validation of a 46-gene cell cycle progression (CCP) RNA signature for predicting prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort.

  • Prolaris measures change in RNA expression levels of multiple genes related to the progression of tumor cell division.
  • This analysis looked to determine if changes in CCP score added to stage, grade, PSA, and extent of disease with regard to the informed management of disease.
  • The endpoint of this analysis was not changes in pathology or Gleason score, but rather patients’ risk of developing metastases and dying of disease.